February 13, 2020
Astellas Pharma/Pfizer’s Xtandi (enzalutamide) demonstrated a significant improvement in overall survival (OS) versus standard-of-care hormone therapy alone in non-metastatic castration-resistant prostate cancer (CRPC), according to final PIII analysis data. The two partners said on February 11 that the androgen receptor...read more